Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene

	Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene
	Xu, B; Zheng, WY; Jin, DY; Wang, DS; Liu, XY; Qin, XY
刊名	CANCER
	2012
卷号	118 期号:21 页码:5217-5226
关键词	cancer-targeting gene virotherapy lipocalin-2 pancreatic cancer oncolytic adenovirus
通讯作者	Xu, B (reprint author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Gen Surg, 301 Yanchang Rd, Shanghai 200072, Peoples R China.,pfdbs1@yahoo.com.cn ; xyliu@sibs.ac.cn ; qin.xinyu@zs-hospital.sh.cn
英文摘要	BACKGROUND: The 5-year survival rate for patients with pancreatic cancer is <5%, and it is always resistant to the current chemoradiotherapy. Therefore, new, effective agents for the treatment of pancreatic cancer are urgently needed. The promising strategy of cancer-targeting gene virotherapy (CTGVT) has demonstrated great anticancer potential. The objective of the current study was to determine whether 1 CTGVT approach, oncolytic virus (OV)-harboring lipocalin-2, is capable of treating pancreatic cancer. METHODS: Tissue microarrays were constructed to detect the expression of lipocalin-2 in 60 specimens of pancreatic adenocarcinoma. The clinical significance of lipocalin-2 was investigated in an analysis of correlations between lipocalin-2 expression and matched clinical characteristics. A lipocalin-2expressing OV, ZD55-lipocalin-2, was constructed by deleting the adenoviral protein E1B55kD. The antitumor efficacy and mechanisms of the OV were investigated in pancreatic cancer cells with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in vitro and in vivo. RESULTS: Lipocalin-2 expression was correlated with a good prognosis in patients with pancreatic adenocarcinoma. ZD55-lipocalin-2 dramatically inhibited the growth of pancreatic cancer in vitro and in vivo by inducing cytolysis and caspase-dependent apoptosis. CONCLUSIONS: Higher lipocalin-2 expression predicted a better prognosis in patients with pancreatic cancer. The results indicated that ZD55-lipocalin-2, which specifically expressed higher levels of lipocalin-2 in tumor cells, may serve as a potent anticancer drug for pancreatic cancer therapy, especially for patients who have pancreatic adenocarcinoma with KRAS mutations. Cancer 2012. (c) 2012 American Cancer Society.
学科主题	Oncology
类目[WOS]	Oncology
关键词[WOS]	GELATINASE-ASSOCIATED LIPOCALIN ; METASTATIC COLORECTAL-CANCER ; ANTITUMORAL EFFICACY ; TRANSFORMED-CELLS ; THERAPY ; VIROTHERAPY ; ADENOVIRUS ; CARCINOMA ; RAS ; GEMCITABINE
收录类别	SCI
语种	英语
WOS记录号	WOS:000310083000005
内容类型	期刊论文
版本	出版稿
源URL	[http://202.127.25.143/handle/331003/685]
专题	上海生化细胞研究所_上海生科院生化细胞研究所
推荐引用方式 GB/T 7714	Xu, B,Zheng, WY,Jin, DY,et al. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene[J]. CANCER,2012,118(21):5217-5226.
APA	Xu, B,Zheng, WY,Jin, DY,Wang, DS,Liu, XY,&Qin, XY.(2012).Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene.CANCER,118(21),5217-5226.
MLA	Xu, B,et al."Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene".CANCER 118.21(2012):5217-5226.